MorphoSys Stock Forecast, Price & News

MorphoSys (NASDAQ:MOR) Frequently Asked Questions

Is MorphoSys a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last twelve months. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MorphoSys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys or view top-rated stocks.

How has MorphoSys' stock been impacted by Coronavirus (COVID-19)?

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MOR stock has decreased by 60.3% and is now trading at $10.03.
View which stocks have been most impacted by COVID-19.

Are investors shorting MorphoSys?

MorphoSys saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 203,100 shares, an increase of 34.7% from the October 31st total of 150,800 shares. Based on an average daily trading volume, of 61,200 shares, the days-to-cover ratio is presently 3.3 days.
View MorphoSys' Short Interest.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for MorphoSys.

What guidance has MorphoSys issued on next quarter's earnings?

MorphoSys updated its FY 2021 earnings guidance on Wednesday, December, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $182.78 million-$212.26 million, compared to the consensus revenue estimate of $197.31 million.

What price target have analysts set for MOR?

13 brokerages have issued twelve-month price targets for MorphoSys' stock. Their forecasts range from $12.00 to $59.00. On average, they expect MorphoSys' stock price to reach $25.46 in the next year. This suggests a possible upside of 153.8% from the stock's current price.
View analysts' price targets for MorphoSys or view top-rated stocks among Wall Street analysts.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:

• Jean-Paul Kress, CEO & Chairman-Management Board
• Roland Wandeler, Chief Operating Officer
• Sung H. Lee, Chief Financial Officer
• Malte Peters, Chief Research & Development Officer
• Armin Weidmann, Head-Compliance & Quality Assurance

What is Simon E. Moroney's approval rating as MorphoSys' CEO?

5 employees have rated MorphoSys CEO Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among MorphoSys' employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of MorphoSys' key competitors?

Some companies that are related to MorphoSys include Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Mawson Infrastructure Group (WIZP), I-Mab (IMAB), Cerevel Therapeutics (CERE), Allakos (ALLK), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Ionis Pharmaceuticals (IONS), Zentalis Pharmaceuticals (ZNTL), Alkermes (ALKS), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA) and Cytokinetics (CYTK).
View all of MOR's competitors.

When did MorphoSys IPO?

(MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

Who are MorphoSys' major shareholders?

MorphoSys' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.62%), Millennium Management LLC (0.29%), Morgan Stanley (0.11%), Renaissance Technologies LLC (0.04%), Henry James International Management Inc. (0.03%) and Marshall Wace LLP (0.02%).

Which institutional investors are selling MorphoSys stock?

MOR stock was sold by a variety of institutional investors in the last quarter, including Henry James International Management Inc., Two Sigma Investments LP, Goldman Sachs Group Inc., and Morgan Stanley.

Which institutional investors are buying MorphoSys stock?

MOR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, US Bancorp DE, and Signaturefd LLC.

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $10.03.

How much money does MorphoSys make?

MorphoSys has a market capitalization of $1.37 billion and generates $374.30 million in revenue each year. The company earns $111.82 million in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does MorphoSys have?

MorphoSys employs 615 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

Where are MorphoSys' headquarters?

MorphoSys is headquartered at SEMMELWEISSTR. 7, PLANEGG 2M, 82152.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company can be reached via phone at (498) 989-9270, via email at [email protected], or via fax at 49-89-8992-7222.